Mlf 541
Digestive System Cancer
B. Braun Melsungen AGUNKNOWNPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
73 Active assets in the Digestive System Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fluorouracilum Alliance for Clinical Trials in Oncology | Phase 2 | BB |
Irinotecan Amgen | Phase 2 | BB |
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Brian Anderson, MD | Phase 4 | BB |
Dexasone Cedars-Sinai Medical Center | Phase 4 | BB |
Marcaine Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →